Experienced in Cervical Cancer

Dr. James P. Ohr

Hematology Oncology | Hematology | Oncology
Oncology Hematology Association Inc
5115 Centre Ave, Fl 3, 
Pittsburgh, PA 
Experienced in Cervical Cancer
Oncology Hematology Association Inc
5115 Centre Ave, Fl 3, 
Pittsburgh, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

James Ohr is a Hematologist Oncology specialist and a Hematologist in Pittsburgh, Pennsylvania. Dr. Ohr is rated as an Experienced provider by MediFind in the treatment of Cervical Cancer. His top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Laryngeal Cancer, Throat Cancer, Pancreatic Cancer, and Gastrostomy.

His clinical research consists of co-authoring 41 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in PA
Hospital Affiliations
Upmc Northwest
Upmc Hamot
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Gateway Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Geisinger
  • HMO
  • POS
  • PPO
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
PA Health and Wellness
  • HMO
  • MANAGED MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

ONCOLOGY HEMATOLOGY ASSOCIATION INC
5115 Centre Ave, Fl 3, Pittsburgh, PA 15232
Call: 412-235-1020
Other Locations
ONCOLOGY HEMATOLOGY ASSOCIATION INC
2500 W 12th St, Erie, PA 16505
Call: 814-838-9000
MRS PHYSICAL THERAPY
4538 Peach St, Erie, PA 16509
Call: 814-864-6650

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Phase II Study of Enzalutamide (NSC# 766085) for Patients With Androgen Receptor Positive Salivary Cancers
A Phase II Study of Enzalutamide (NSC# 766085) for Patients With Androgen Receptor Positive Salivary Cancers
Enrollment Status: Active_not_recruiting
Publish Date: February 11, 2026
Intervention Type: Drug
Study Drug: Enzalutamide
Study Phase: Phase 2
A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients With Advanced, EGFR Mutation Positive Non-small Cell Lung Cancer (NSCLC)
A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients With Advanced, EGFR Mutation Positive Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: February 06, 2026
Intervention Type: Drug, Other, Biological
Study Drugs: Afatinib Dimaleate, Cetuximab
Study Phase: Phase 2/Phase 3
Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI With PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer
Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI With PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 01, 2025
Intervention Type: Drug, Other
Study Drugs: Fluorouracil, Irinotecan Hydrochloride, Leucovorin Calcium, Veliparib
Study Phase: Phase 2
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Enrollment Status: Active_not_recruiting
Publish Date: December 01, 2025
Intervention Type: Procedure, Drug, Other
Study Drugs: Cediranib, Cediranib Maleate, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan, Topotecan Hydrochloride
Study Phase: Phase 2/Phase 3
Utilization of Low Level Laser Therapy for Radiation Induced Dermatitis in Patients With Head and Neck Squamous Cell Carcinoma
Utilization of Low Level Laser Therapy for Radiation Induced Dermatitis in Patients With Head and Neck Squamous Cell Carcinoma
Enrollment Status: Completed
Publish Date: June 27, 2025
Intervention Type: Device
Study Phase: Not Applicable
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Selpercatinib, Cabozantinib, Vandetanib
Study Phase: Phase 3
A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
Enrollment Status: Active_not_recruiting
Publish Date: February 13, 2025
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
Phase II Study for Curative Intent Treatment for Patients With Oligometastatic Disease at Initial Presentation
Phase II Study for Curative Intent Treatment for Patients With Oligometastatic Disease at Initial Presentation
Enrollment Status: Terminated
Publish Date: October 11, 2023
Intervention Type: Radiation, Drug
Study Phase: Phase 2
Randomized Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Randomized Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Enrollment Status: Completed
Publish Date: June 05, 2023
Intervention Type: Drug, Radiation
Study Drugs: Cetuximab, Docetaxel
Study Phase: Phase 2
Phase II Study of Stereotactic Radiosurgery for Patients With Oligo-recurrent Disease
Phase II Study of Stereotactic Radiosurgery for Patients With Oligo-recurrent Disease
Enrollment Status: Completed
Publish Date: May 19, 2023
Intervention Type: Radiation
Study Phase: Not Applicable
A Phase II Prospective Trial of Low-Level Laser Therapy for Prevention of Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer
A Phase II Prospective Trial of Low-Level Laser Therapy for Prevention of Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer
Enrollment Status: Completed
Publish Date: April 13, 2022
Intervention Type: Device
Study Phase: Not Applicable
Observational Study of Metastatic Prostate Cancer Subjects Receiving Docetaxel Therapy for Evaluation of Docetaxel Plasma Levels Using the MyDocetaxel Assay
Observational Study of Metastatic Prostate Cancer Subjects Receiving Docetaxel Therapy for Evaluation of Docetaxel Plasma Levels Using the MyDocetaxel Assay
Enrollment Status: Completed
Publish Date: February 17, 2022
Intervention Type: Other, Drug
View 11 Less Clinical Trials

42 Total Publications

Phase Ib study of berzosertib, carboplatin, gemcitabine, and pembrolizumab in patients with squamous nonsmall lung cancer (ETCTN 10313).
Phase Ib study of berzosertib, carboplatin, gemcitabine, and pembrolizumab in patients with squamous nonsmall lung cancer (ETCTN 10313).
Journal: The oncologist
Published: July 09, 2025
View All 42 Publications
Similar Doctors
Distinguished in Cervical Cancer
Dr. Madeleine B. Courtney-Brooks
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Distinguished in Cervical Cancer
Dr. Madeleine B. Courtney-Brooks
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

University Of Pittsburgh Physicians

300 Halket St, 
Pittsburgh, PA 
 (1.5 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Madeleine Courtney-Brooks is a Gynecologic Oncologist and an Oncologist in Pittsburgh, Pennsylvania. Dr. Courtney-Brooks is rated as a Distinguished provider by MediFind in the treatment of Cervical Cancer. Her top areas of expertise are Endometrial Cancer, Vulvar Cancer, Cervical Cancer, Vulvectomy, and Hysterectomy.

Robert P. Edwards
Advanced in Cervical Cancer
Dr. Robert P. Edwards
Oncology
Advanced in Cervical Cancer
Dr. Robert P. Edwards
Oncology

University Of Pittsburgh Physicians, Department Of Women's Health

9100 Babcock Boulevard, Ground Level, 
Pittsburgh, PA 
 (8.4 miles away)
412-981-5436
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Robert P. Edwards, MD, is the Chair of Ob/Gyn/RS at  UPMC Magee-Womens Hospital. Dr. Edwards is co-leader of the UPMC Gynecologic Cancer Program, and a professor of medicine in the Department of Obstetrics, Gynecology, and Reproductive Sciences at the University of Pittsburgh School of Medicine.Dr. Edwards specializes in all aspects of gynecologic oncology, and has a particular interest in intraperitoneal chemotherapy. and immunotherapty. Dr. Edwards is board-certified in obstetrics and gynecology, as well as gynecologic oncology. He received an undergraduate degree at Gettysburg College in Gettysburg, Pa., and received a medical degree at the University of Pittsburgh School of Medicine. Dr. Edwards completed a residency in obstetrics and gynecology at Magee-Womens Hospital of UPMC, and a fellowship in gynecologic oncology at the University of Alabama at Birmingham. Dr. Edwards is a member of professional organizations including the University of Pittsburgh Physicians Board of Directors, American Medical Association, American College of Surgeons, American College of Obstetricians and Gynecologists, American Association for Cancer Research, American Society of Clinical Oncology, Society of Gynecologic Oncologists, American Society of Colposcopy and Cervical Pathology, International Society for Biological Therapy of Cancer, American Association for the Advancement of Science, and the International Gynecologic Cancer Society. Dr. Edwards is rated as a Distinguished provider by MediFind in the treatment of Cervical Cancer. His top areas of expertise are Ovarian Cancer, Endometrial Cancer, Vaginal Cancer, Hysterectomy, and Vulvectomy.

Advanced in Cervical Cancer
Dr. Jamie L. Lesnock
Obstetrics and Gynecology | Oncology
Advanced in Cervical Cancer
Dr. Jamie L. Lesnock
Obstetrics and Gynecology | Oncology

University Of Pittsburgh Physicians

300 Halket St, 
Pittsburgh, PA 
 (1.5 miles away)
412-641-1000
Languages Spoken:
English
See accepted insurances

Jamie Lesnock is an Obstetrics and Gynecologist and an Oncologist in Pittsburgh, Pennsylvania. Dr. Lesnock is rated as a Distinguished provider by MediFind in the treatment of Cervical Cancer. Her top areas of expertise are Endometrial Cancer, Ovarian Cancer, Ovarian Carcinosarcoma, Hysterectomy, and Ureteral Reconstruction.

VIEW MORE CERVICAL CANCER DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ohr's expertise for a condition
ConditionClose
    • Distinguished
    • Colorectal Cancer
      Dr. Ohr is
      Distinguished
      . Learn about Colorectal Cancer.
      See more Colorectal Cancer experts
    • Familial Pancreatic Cancer
      Dr. Ohr is
      Distinguished
      . Learn about Familial Pancreatic Cancer.
      See more Familial Pancreatic Cancer experts
    • Head and Neck Squamous Cell Carcinoma (HNSCC)
      Dr. Ohr is
      Distinguished
      . Learn about Head and Neck Squamous Cell Carcinoma (HNSCC).
      See more Head and Neck Squamous Cell Carcinoma (HNSCC) experts
    • Laryngeal Cancer
      Dr. Ohr is
      Distinguished
      . Learn about Laryngeal Cancer.
      See more Laryngeal Cancer experts
    • Pancreatic Cancer
      Dr. Ohr is
      Distinguished
      . Learn about Pancreatic Cancer.
      See more Pancreatic Cancer experts
    • Throat Cancer
      Dr. Ohr is
      Distinguished
      . Learn about Throat Cancer.
      See more Throat Cancer experts
    • Advanced
    • Acinic Cell Carcinoma of Salivary Glands
      Dr. Ohr is
      Advanced
      . Learn about Acinic Cell Carcinoma of Salivary Glands.
      See more Acinic Cell Carcinoma of Salivary Glands experts
    • Adenoid Cystic Carcinoma
      Dr. Ohr is
      Advanced
      . Learn about Adenoid Cystic Carcinoma.
      See more Adenoid Cystic Carcinoma experts
    • ALK-Positive Non-Small Cell Lung Cancer
      Dr. Ohr is
      Advanced
      . Learn about ALK-Positive Non-Small Cell Lung Cancer.
      See more ALK-Positive Non-Small Cell Lung Cancer experts
    • EGFR Positive Lung Cancer
      Dr. Ohr is
      Advanced
      . Learn about EGFR Positive Lung Cancer.
      See more EGFR Positive Lung Cancer experts
    • Epithelial-Myoepithelial Carcinoma
      Dr. Ohr is
      Advanced
      . Learn about Epithelial-Myoepithelial Carcinoma.
      See more Epithelial-Myoepithelial Carcinoma experts
    • Familial Colorectal Cancer
      Dr. Ohr is
      Advanced
      . Learn about Familial Colorectal Cancer.
      See more Familial Colorectal Cancer experts
    View All 23 Advanced Conditions
    • Experienced
    • Acute Myeloblastic Leukemia with Maturation
      Dr. Ohr is
      Experienced
      . Learn about Acute Myeloblastic Leukemia with Maturation.
      See more Acute Myeloblastic Leukemia with Maturation experts
    • Acute Myeloblastic Leukemia without Maturation
      Dr. Ohr is
      Experienced
      . Learn about Acute Myeloblastic Leukemia without Maturation.
      See more Acute Myeloblastic Leukemia without Maturation experts
    • Acute Myeloid Leukemia (AML)
      Dr. Ohr is
      Experienced
      . Learn about Acute Myeloid Leukemia (AML).
      See more Acute Myeloid Leukemia (AML) experts
    • Adrenal Cancer
      Dr. Ohr is
      Experienced
      . Learn about Adrenal Cancer.
      See more Adrenal Cancer experts
    • Adult Soft Tissue Sarcoma
      Dr. Ohr is
      Experienced
      . Learn about Adult Soft Tissue Sarcoma.
      See more Adult Soft Tissue Sarcoma experts
    • Agranulocytosis
      Dr. Ohr is
      Experienced
      . Learn about Agranulocytosis.
      See more Agranulocytosis experts
    View All 121 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved

      Request an Appointment

      If you are experiencing a medical emergency, call 9-1-1.

      MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

      Patient Details

      This information is for the patient who will be seen at the appointment.

        Close

        Returning patient? Use your address on file with the provider.

        Insurance Details

        Please provide information of the primary insurance holder as the practice may require this information to schedule.

        Insurance Provider *
        Insurance ProviderClose

        Appointments Details

        Let’s get more information about your appointment.

                0 / 1000
                0 / 1000
                By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.